Evidence map›Paper›PMID 27129221›Full record

ArticleThe Journal of biological chemistry2016

Regulation of Bone Morphogenetic Protein Signaling by ADP-ribosylation.

Yukihide Watanabe, Panagiotis Papoutsoglou, Varun Maturi, Yutaro Tsubakihara, Michael O Hottiger, Carl-Henrik Heldin, Aristidis Moustakas

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Yukihide WatanabeFrom Ludwig Cancer Research, Science for Life Laboratory, Uppsala University, SE-751 24 Uppsala, Sweden.
Panagiotis PapoutsoglouFrom Ludwig Cancer Research, Science for Life Laboratory, Uppsala University, SE-751 24 Uppsala, Sweden.
Varun MaturiFrom Ludwig Cancer Research, Science for Life Laboratory, Uppsala University, SE-751 24 Uppsala, Sweden.
Yutaro TsubakiharaFrom Ludwig Cancer Research, Science for Life Laboratory, Uppsala University, SE-751 24 Uppsala, Sweden.
Michael O Hottigerthe Department of Molecular Mechanisms of Disease, University of Zurich, 8057 Zurich, Switzerland, and.
Carl-Henrik HeldinFrom Ludwig Cancer Research, Science for Life Laboratory, Uppsala University, SE-751 24 Uppsala, Sweden.
Aristidis MoustakasFrom Ludwig Cancer Research, Science for Life Laboratory, Uppsala University, SE-751 24 Uppsala, Sweden,; the Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, SE-751 23 Uppsala, Sweden. Electronic address: aris.moustakas@imbim.uu.se.
Uppsala University · SEScience for Life Laboratory · SELudwig Cancer Research · SEUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously established a mechanism of negative regulation of transforming growth factor β signaling mediated by the nuclear ADP-ribosylating enzyme poly-(ADP-ribose) polymerase 1 (PARP1) and the deribosylating enzyme poly-(ADP-ribose) glycohydrolase (PARG), which dynamically regulate ADP-ribosylation of Smad3 and Smad4, two central signaling proteins of the pathway. Here we demonstrate that the bone morphogenetic protein (BMP) pathway can also be regulated by the opposing actions of PARP1 and PARG. PARG positively contributes to BMP signaling and forms physical complexes with Smad5 and Smad4. The positive role PARG plays during BMP signaling can be neutralized by PARP1, as demonstrated by experiments where PARG and PARP1 are simultaneously silenced. In contrast to PARG, ectopic expression of PARP1 suppresses BMP signaling, whereas silencing of endogenous PARP1 enhances signaling and BMP-induced differentiation. The two major Smad proteins of the BMP pathway, Smad1 and Smad5, interact with PARP1 and can be ADP-ribosylated in vitro, whereas PARG causes deribosylation. The overall outcome of this mode of regulation of BMP signal transduction provides a fine-tuning mechanism based on the two major enzymes that control cellular ADP-ribosylation.

Indexed as

Adenosine Diphosphate RiboseAnimalsBone Morphogenetic ProteinsCell LineCells, CulturedDNA-Binding ProteinsGene ExpressionGlycoside HydrolasesHEK293 CellsHumansImmunoblottingMice, KnockoutProtein BindingReverse Transcriptase Polymerase Chain ReactionRNA InterferenceSignal TransductionAdenosine Diphosphate RiboseBone Morphogenetic ProteinsDNA-Binding ProteinsGlycoside HydrolasesPARPBP protein, humanpoly ADP-ribose glycohydrolaseSmad4 ProteinSmad5 ProteinADP-ribosylationbone morphogenetic protein (BMP)signal transductionSMAD transcription factortranscription

Identifiers

PMID27129221
PMCPMC4933475
OpenAlexW2337632357

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.